Compare Repligen Corporation Common Stock (RGEN) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Schwab US Large Cap Growth ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Schwab US Large Cap Growth ETF trades at $35.64 (market cap $65.41B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 5.9× Repligen Corporation Common Stock's market cap, and Schwab US Large Cap Growth ETF is more actively traded (6,607,358 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Schwab US Large Cap Growth ETF for 52 Days on average.
| RGEN | SCHG | |
|---|---|---|
Market Cap | $11.14B | $65.41B |
Volume | 1,259,263 | 6,607,358 |
Sector | Health | Sector/Thematic |
52-Week High | $194.57 | $36.93 |
52-Week Low | $102.87 | $28.10 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SCHG trades at $36.59 with no daily change, showing stability amid a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent 20% position reduction by Corient Private Wealth. Recent news highlights SCHG's competitive positioning among large-cap growth ETFs with its 0.03% expense ratio and concentration in megacap technology stocks.
The outlook remains positive given SCHG's historical outperformance versus the S&P 500, though concentration risk in top holdings and potential valuation concerns warrant monitoring. Growth investors may benefit from the ETF's low-cost exposure to leading US companies, but should be aware of narrowing performance gaps with broader market alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
